Bharat Biotech to launch Covaxin in the second quarter of 2021
The company recently received DCGI approval to conduct Phase-3 clinical trial
Covaxine is developed in collaboration with ICMR and National Institute of Virology
About 2,000 participants will be enrolled for the trials in 25 to 30 sites across 14 states
Vaccine price will be determined after ensuring the complete success of the trials
